Gastric Balloon

Use of a swallowable gastric balloon in conjunction with a GLP-1 receptor agonist induced a mean weight loss of approximately 19% for adults with overweight or obesity, according to a speaker.

The FDA on Monday issued a Letter to Health Care Providers detailing risks for hyperinflation and acute pancreatitis observed in post-approval studies for two liquid-filled intragastric balloons indicated for weight loss, both approved in 2015 and manufactured by Apollo Endosurgery.

Endoscopic management has a clear role in the future of obesity care, with multiple options available for patients, according to an expert at the GUILD Conference 2020.

Currently, gastroenterologists and other physicians have quite a few options to treat overweight and obesity, but at times that is overwhelming.